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BACKGROUND: Production of antibodies that are spe-
cific for allergens is an important pathological pro-
cess in inflammatory allergic diseases. These contain
the antibodies against antigens of Candida albicans,
one of the normal microbial flora in an intestinal
tract. We studied the effects of the prednisolone
administration on the production of anti-Candida
antibodies in the gastrointestinally C. albicans-colo-
nized mice.
Methods and Materials: BALB/c mice, treated with
antibacterial antibiotics to decontaminate indigenous
intestinal bacterial flora, were inoculated intragastri-
cally with C. albicans. The mice, in which C. albicans
grows intestinally, were administered prednisolone
to induce temporary immunosuppression. The Can-
dida growth in their intestinal tract and their anti-
body response to Candida were examined.
Results: Antibiotic treatment allowed establishment
of C. albicans gastrointestinal colonization, but did
not cause subsequent systemic dissemination of C.
albicans in all the animals. When these animals
received an additional treatment with prednisolone,
they showed a significantly higher population of C.
albicans in their feces than those of animals treated
with antibiotics alone, and the organisms were
recovered even from their kidney. This systemic
dissemination by C. albicans appeared to be tempor-
al, because all the mice survived without any
symptoms for more than 2 months. Examination of
the serum titers of total immunoglobulin (Ig)E
antibodies and specific IgE and IgG antibodies against
Candida antigens demonstrated that titers of total IgE
increased, partially by day 14 and clearly at day 27, in
prednisolone-treated Candida-colonized mice. With-
out prednisolone treatment, an increment of the
serum titer was scarcely observed. By day 27,
corresponding to the increase of total IgE, the anti-
Candida IgE and IgG titer increased in mice of the
prednisolone-treated group.
Conclusion: Administration of prednisolone to Can-
dida-colonized mice can induce production of the
IgG, IgE antibodies against Candida antigens, per-
haps through temporal systemic dissemination of
Candida from the intestinal tract.
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Introduction
Candida albicans is known to be one of the
intestinal microbial flora of healthy persons.
1 To this
microbe, adults elicit cellular and/or humoral im-
mune responses postulated to have some pathoge-
netic relevance to such allergic diseases as atopic
dermatitis (AD)
27 and food allergy.
8 Savolainen et
al. reported that AD patients frequently have a high
titer of anti-C. albicans antibodies in their sera.
9
Candida organisms are colonized in the intestinal
tracts in these patients and are harbored in the nasal
cavity and buccal capsule in a saprophytic manner at
high frequency, and a high titer of immunoglobulin
(Ig)E antibody reacting with Candida is frequently
detectable.
9 Moreover, several recent examples have
shown that oral administration of antifungal agents to
AD patients has displayed therapeutic efficacy with
improvement of dermatitis.
4,10,11
To study the pathogenetic roles of C. albicans in
these allergic diseases, it is important to analyze the
induction process of anti-Candida IgE and/or IgG
antibodies in Candida-colonized individuals. How-
ever, it is not yet known how specific Candida IgE
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189antibodies are produced in modern human life. We
assumed that intestinal translocation of Candida
organisms might provide immunogenic stimulation
to produce specific IgE and/or IgG antibodies. We
reported previously that application of antibiotics and
anti-inflammatory corticosteroids induced an over-
growth of C. albicans in the intestinal tract of mice.
12
Here, we find that prednisolone treatment of mice
intestinally colonized by C. albicans induced pro-
duction of specific IgE and IgG antibodies, perhaps
through systemic dissemination of this fungus from
the gut.
Materials and methods
Preparation of Candida inoculate for challenge
C. albicans TIMM 0239
12,13 was grown in Sabouraud
dextrose broth in an L-tube. After growing at 378C
overnight, cells were harvested by centrifugation,
washed three times with saline, and adjusted to a cell
density appropriate for inoculation to mice.
Animals and inoculation
All animal experiments were performed according to
the guidelines for the care and use of animals
approved by Teikyo University. To produce intestin-
ally C. albicans-colonized mice, we used a modified
method of Uchida et al.
13 Specific pathogen-free
female BALB/c mice, 6/8 weeks old (Japan SLC, Inc.,
Shizuoka, Japan) were given potable water contain-
ing 1 mg/ml of ampicillin (Meiji Seika Co., Tokyo,
Japan) and 0.2 mg/ml of kanamycin (Meiji Seika Co.)
until the end of the experiments. Each mouse was
challenged intragastrically with 1 /10
6 cells of C.
albicans at a volume of 0.1 ml using a gastric gavage.
For immunosuppression, animals were subcuta-
neously given 100 mg/kg body weight of predniso-
lone (Mitaka Seiyaku, Tokyo, Japan) 7 and 9 days
after the Candida challenge as described else-
where.
12 Intestinal colonization of C. albicans was
monitored by counts of viable C. albicans cells in
their stools as follows. Every stool sample was
homogenized in a volume of sterile saline and serial
10-fold dilutions with saline were made. One hun-
dred microliters of each dilution was inoculated onto
Candida GS agar (Tanabe Seiyaku Co. Ltd, Osaka,
Japan) and the cultures were incubated at 378C for 24
h, at which time quantitation of fungal colonies was
performed. In some experiments, Candida-chal-
lenged mice were killed for microbial examination;
kidneys were excised aseptically and homogenized
in a glass tissue grinder with 1 ml of saline. Viable
Candida cells were counted as already described,
and the results were expressed as the mean
9 /standard deviation value of colony-forming units
(CFU) per kidneys of five mice in each group.
Enzyme-linked immunosorbent assay
The total IgE level was measured by a sandwich
enzyme-linked immunosorbent assay (ELISA) using
two kinds of rat anti-mouse IgE monoclonal antibody
(mAb) (6HD5 and HMK12) according to the instruc-
tions of the manufacturer (Yamasa Shoyu Co., Ltd.,
Choshi, Japan).
14 These mAbs recognized different
epitopes of Fc fragments of murine IgE. Briefly, 96
wells of solid immunomicroplates (Nunc) were
coated with 50 ml of 6HD5 mAb (5 ml/ml) and
blocked with phosphate-buffered saline supple-
mented with 1% bovine serum albumin (Sigma
Chemical Co., St Louis, MO, USA). Collected samples
or standard mouse IgE (SPE7; Seikagaku Kogyo,
Tokyo, Japan) were added to the wells and incubated
for 1 h at room temperature. Each well was washed
with phosphate-buffered saline containing 0.05%
Tween-20, and received 50 ml of biotinylated
HMK12 mAb (1 mg/ml), and then all the plates were
incubated for 1 h. After 50 ml of peroxidase-con-
jugated avidin (1/2000; Dakopatts, Glostrup, Den-
mark) was added to each well, another 1 h
incubation was carried out. Finally, the reaction
products were visualized with 0.4 mg/ml of ortho-
phenylenediamine (Sigma) and 0.012% H2O2. Thirty
minutes after addition of the substrate, the reaction
was stopped with 0.05 ml of 0.2 M H2SO4 and the
absorbance at 490 nm wavelength was measured by
an Immunoreader (NJ-2300; Nippon Intermed, To-
kyo, Japan). In this assay the minimal detectable
concentration of IgE was 40 ng/ml.
Specific IgE for Candida antigens was measured
by an ELISA as described previously
14 with slight
modifications. A Candida antigen preparation was
obtained from C. albicans cells by 37C 2 h incubation
in 0.05 M citrate buffer (pH 7) as described else-
where.
1517 Immunomicroplates for ELISA (Nunc)
were coated with the Candida antigen preparation
(0.75 mg protein/ml). Serum samples were incubated
in the Candida antigen-coated microwells for 1 h.
Then, binding of IgE antibodies with the Candida
antigens was detected by rat
anti-mouse IgE mAb (biotinylated HMK12 mAb)
and peroxidase-conjugated avidin as already
described.
Statistical analysis
Statistical difference in the survival rate was exam-
ined by Wilcoxon test. Other statistical analyses were
examined by Student’s t-test.
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Effects of treatments with antibiotics and/or
prednisolone on intestinal colonization of C.
albicans in mice
The effects of treatments to mice with two antibacter-
ial agents, ampicillin and kanamycin, and/or predni-
solone on the intestinal colonization of C. albicans
were examined. BALB/c mice taking antibacterial
agent-supplemented or unsupplemented drinking
water were orally infected with C. albicans.A s
shown in Fig. 1, viable Candida cells were recovered
from the feces of the Candida-inoculated mice from
the day following oral inoculation (day 1). On this
day the mean CFU number of Candida in the stools
of mice given the supplemented drinking water was
about 1 /10
5 CFU/g of stool. The viable Candida
population in the stools of mice given the unsupple-
mented drinking water rapidly decreased to a level of
less than 1 /10
4 CFU/g on day 3. On the other hand,
antibiotic-treated mice maintained a high concentra-
tion of C. albicans of about 1 /10
7 CFU/g for more
than 2 weeks.
Figure 1 also shows that two subcutaneous
administrations of prednisolone increased the CFU
level about 10-fold in the antibiotic-treated mice. To
check the systemic dissemination of C. albicans from
intestinal colonization in these mice, their kidney
homogenates of their kidney were cultured on
Candida-GS-agar. As shown in Fig. 2, in mice treated
with prednisolone at days 7 and 9, Candida cells
were detected on day 11 and the number of CFU in
their kidney increased to 5 /10
5 CFU/g on day 13,
but the mice tested survived for more than 1 month.
This indicates that the prednisolone treatment caused
temporal systemic dissemination of C. albicans 2
weeks after the infection but did not result in
Candida infection fatal to the hosts.
Antibody-formation of orally Candida-infected
mice with or without prednisolone treatment
Total IgE concentration in sera of these Candida-
infected mice at 2 and 4 weeks after Candida
infection was measured. As shown in Fig. 3, in
comparison with normal mice, a low but significant
level of IgE (less than 100 ng/ml) could be detected
in the sera of the antibiotic-treated and Candida-
colonized mice at 2 weeks after the challenge.
Prednisolone treatments of such mice clearly in-
creased the serum level of IgE of the animals to
about 120 ng/ml and 200/300 ng/ml at 2 and 4
weeks after the challenge, respectively.
In further experiments, the titers of IgE and IgG
antibodies against Candida antigen in the sera of the
C. albicans-colonized mice at 4 weeks after the
challenge were examined. Figures 4 and 5 show
that IgE and IgG, respectively, against Candida
antigens increased in the serum of the animals treated
with antibiotics and infected orally with C. albicans
and twice administered with prednisolone. Without
the treatment with both prednisolone and antibiotics,
these infected mice would had no sera showing a
detectable level of antibodies against Candida anti-
gens higher than those of control mice.
FIG. 1. Viable Candida cells in feces of C. albicans-infected
mice treated with prednisolone. BALB/c mice were given
potable water with (open symbols) and without antibiotic
(closed symbols). Mice were infected with 10
6 CFU of C.
albicans in their intestinal tracts, then were subcutaneously
given 100 mg/kg of prednisolone (closed squares, open
squares) or saline (closed circles, open circles) at 7 and 9
days after this infection, respectively. Feces counts were
determined at time points thereafter. The results are ex-
pressed as a viable count obtained from groups of nine mice
per data point.
FIG. 2. Viable Candida cells in the kidney of C. albicans-
infected mice treated with or without prednisolone. BALB/c
mice were infected with 10
6 CFU of C. albicans in their
intestinal tracts, then were subcutaneously given 100 mg/kg
of prednisolone (squares) and Saline (circles) at 7 and 9 days
after this infection. Candida cell counts in kidney were
determined at time points thereafter. The results are ex-
pressed as a viable count obtained from groups of nine mice
per data point.
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caused a significant increase in specific Candida IgE
and IgG antibodies in the sera of Candida-colonized
mice.
Discussion
We have shown that prednisolone administration to
mice with intestinally-colonized C. albicans induced
IgG and IgE antibodies in their sera within 4 weeks
after infection. As far as we know, this is the first
report that administration of anti-inflammatory ster-
oidal compounds causes production of anti-Candida
antibodies in Candida-colonized animals. Antibody
production augmented by prednisolone treatment is
not curious, because immunosuppressive activity of
prednisolone subcutaneously given in the depo-
suspension form is known to disappear within 1
week after administration.
The mechanism of the augmentation of antibody
production by prednisolone remains to be clarified.
We believe that prednisolone treatment must have a
profound effect on the immunological condition of
the mice, since the concentration of total IgE
immunoglobulin in the sera clearly increased to
200/300 ng/ml in prednisolone-treated Candida
infected mice. We can speculate that the augmenta-
tion of anti-Candida IgE production by prednisolone
treatment may result from in vivo antigen stimulation
accompanied by temporal systemic dissemination of
Candida from the intestinal tract, since Candida
dissemination to kidney was observed in the Can-
dida infected prednisolone treated mice at 6 days
after prednisolone treatment, as shown in Fig. 2. This
speculation is supported by the finding that no
augmented production of IgE or IgG against Can-
dida antigens was observed in either antibiotic-
treated or prednisolone-treated mice unless they
had been orally inoculated with C. albicans (Figs 4
and 5)
The findings presented here may have some
impact on the field of questions among clinical
dermatologists of why steroidal anti-inflammatory
drugs sometimes have a negative effect on the
pathogenesis of AD. AD shows chronic symptoms
with clinical manifestation of repeated aggravating
itching and high concentration of IgE in sera. In AD
patients dermal mast cells bind with IgE; when these
FIG. 3. Total serum IgE levels in C. albicans-infected mice
treated with prednisolone. Serum levels were tested at 2
weeks (open circles) and 4 weeks (closed circles) after the
Candida infections. Total IgE were measured using a speciﬁc
ELISA as described in Materials and methods. Detection
limits of total IgE were 40 ng/ml. *pB /0.05, when compared
with the control (normal mouse serum).
FIG. 5. Enhanced production of anti-Candida antibody (Ig G) in sera of C. albicans-infected mice treated with prednisolone.
Serum levels of antibodies were tested 4 weeks after the Candida infections. Speciﬁc IgG of anti-Candida antibody was
measured using a speciﬁc ELISA as described in Materials and methods. Each value represents the mean9 /standard error of
ﬁve mice per group. *pB /0.05, when compared with the control (normal mouse serum).
FIG. 4. Enhanced production of anti-Candida antibody (IgE)
in sera of C. albicans-infected mice treated with predniso-
lone. Serum levels of antibodies were tested 4 weeks after
the Candida infections. Speciﬁc IgE of anti-Candida antibody
was measured using a speciﬁc ELISA as described in
Materials and methods. Each value represents the mean9 /
standard error of ﬁve mice per group. *pB /0.05, when
compared with the control (normal mouse serum).
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chemical mediator histamine that induces pathologi-
cal symptoms of edema and itching. Severe itching
makes patients scratch their skin, perturbing/disturb-
ing the epidermal organization of epidermal cells and
destroying the barrier of the skin so that it is invaded
by many allergens, worsening the dermatitis. These
suggest that a high concentration of IgE in patient
sera plays a critical role in the pathogenesis of AD.
Our results therefore mean that a steroidal anti-
inflammatory drug may have a severe pathogenic
effect on AD patients because of the augmented
production of IgE. However, at the present time, we
cannot precisely explain the relationship among the
administration of a steroid drug, intestinal transloca-
tion of Candida and pathogenesis of AD. To clarify
this relation, we hope that our model in which anti-
Candida IgE production can be induced by pre-
dnisolone treatment will be used as a tool to analyze
the relationships between anti-inflammatory agents
and IgE allergy with Candida infection.
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